The US Patent Trial and Appeal Board (PTAB) has decided that the Saint Regis Mohawk Tribe cannot claim sovereign immunity from inter partes review (IPR) of Allergan’s patents covering Restasis, and that the IPR proceedings on those patents can continue with Allergan as the patent owner.
The US Patent Trial and Appeal Board (PTAB) has decided that the Saint Regis Mohawk Tribe cannot claim sovereign immunity from inter partes review (IPR) of Allergan’s patents covering Restasis, and that the IPR proceedings on those patents can continue with Allergan as the patent owner.
The decision stems from Allergan’s 2017 transfer of patents covering its dry-eye drug to the Tribe in exchange for invoking sovereign immunity from IPRs. The move came less than 1 week before a scheduled oral hearing for several instituted IPRs of patents covering Restasis. The Tribe then moved to dismiss the scheduled proceedings for lack of jurisdiction.
After considering numerous amicus briefs (and the supplemental briefs of both the petitioners and the patent owners), the PTAB determined that “…the Tribe has not established that the doctrine of tribal sovereign immunity should be applied to these proceedings. Furthermore, we determine that these proceedings can continue even without the Tribe’s participation in view of Allergan’s retained ownership interests in the challenged patents.”
Among the reasons for its decision, says the PTAB, is that tribal sovereignty is subject to the superior control of Congress, and that acts of Congress apply to tribes. Thus, since Congress has enacted a statute that stipulates that any patent is subject to the requirements of law, including IPRs, tribal ownership of a patent does not shield the owner from an IPR proceeding.
Furthermore, the PTAB agreed with the petitioners in their claim that Allergan is the true owner of the patents in question, regardless of how Allergan and the Tribe characterized their arrangement. The PTAB addresses the following among its reasons for the decision:
However, the PTAB did not address the question of whether the arrangement between the Tribe and Allergan was proper; in October 2017, Judge William C. Bryson, who presided over an unrelated Hatch-Waxman litigation concerning Restasis, called for briefs addressing “…whether the assignment of the patents to the Tribe should be disregarded as a sham.” Bryson later invalidated the patents in question in this case.
In its decision, the PTAB wrote that, “In reaching this conclusion, we do not comment on whether the License and the other agreements between the Tribe and Allergan constitute a ‘sham’ transaction, nor do we need to decide whether the agreements are otherwise improper under the law.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.